| | All () | D+/R- () | D+/R+ () | value |
| | Age, yr, mean (SD) | | | | 0.082 | | Weight, kg, mean (SD) | | | | 0.535 | | Gender, male, (%) | 17 (73.9) | 10 (71.4) | 7 (77.8) | 1.000 | | Cause of ESRD, (%) | | | | 0.815 | | Glomerulonephritis | 19 (82.6) | 12 (85.7) | 7 (77.8) | | | Hypertension | 2 (8.7) | 1 (7.1) | 1 (11.1) | | | Polycystic kidney disease | 1 (4.3) | 1 (7.1) | 0 | | | Diabetes mellitus | 1 (4.3) | 0 | 1 (11.1) | | | Blood type, (%) | | | | 0.360 | | B | 8 (34.8) | 5 (35.7) | 3 (33.3) | | | A | 7 (30.4) | 3 (21.4) | 4 (44.4) | | | AB | 4 (17.4) | 4 (28.6) | 0 | | | O | 4 (17.4) | 2 (14.3) | 2 (22.2) | | | Dialysis time, mon, median (IQR) | 18 (10-31) | 16.5 (8.7-28.7) | 18 (10.5-40) | 0.654 | | Prior transplant, yes, (%) | 1 (4.3) | 1(7.1) | 0 | 1.000 | | HLA mismatch, mean (SD) | | | | 0.183 | | APRI (pretransplantation) | | | | 0.059 | | Induction immunosuppression (, %) | | | | | | Basiliximab | 7 (0.30) | 3 (21.4) | 4 (44.4) | 0.242 | | ATG | 14 (0.61) | 10 (71.4) | 4 (44.4) | 0.196 | | No-use | 2 (0.09) | 1 (7.1) | 1 (11.1) | 0.742 | | SVR12 | 100% | 100% | 100% | 0.801 | | HCV viral load at treatment start (log 10 IU/mL), median (IQR) | 4.26 (2.90-5.90) | 3.61 (2.57-4.57) | 5.98 (5.28-6.53) | 0.002 | | Abnormal liver year, (%) | 5 (21.7) | 1 (7.1) | 4 (44.4) | 0.056 | | ALT at 3-month posttransplant, mean (SD) | | | | 0.298 | | ALT at 6-month posttransplant, mean (SD) | | | | 0.801 | | Delayed graft function, (%) | 9 (39.1) | 6 (42.9) | 3 (33.3) | 1.000 | | Acute year, (%) | 3 (13.0) | 2 (14.3) | 1 (11.1) | 1.000 | | eGFR at 3-month posttransplant, mean (SD) | | | | 0.746 | | eGFR at 6-month posttransplant, mean (SD) | | | | 0.798 | | 1-year death-censored graft survival | 100% | 100% | 100% | | | 1-year patient survival | 100% | 100% | 100% | |
|
|
